In order to prevent spam,
this email address cannot be copied.
Researcher Profile - Avi Friedlich Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Community: Researcher Profiles
Researcher Profile

RESEARCHER INFORMATION
First Name:Avi
Last Name:Friedlich
Title:Chief, Research & Development
Advanced Degrees:M.D.
Affiliation:Los Alamos Therapeutics, Inc.
Department:Research & Development
Street Address 1:105 Webster Street
Street Address 2:Building 6
City:Hanover
State/Province:MA
Zip/Postal Code:02339
Country/Territory:U.S.A.
Phone:617-347-7643
Fax:617-963-8959
Email Address: 
Disclosure:
(view policy)  		Member reports no financial or other potential conflicts of interest. [Last Modified: 16 May 2011]
View all comments by Avi Friedlich
Work Sector(s):
University
Researcher Bio
Dr. Friedlich's main interest is in translational research for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and for neuropsychiatric conditions, such as bipolar disorder and schizophrenia. His work spans the length of the pipeline, from target identification to clinical trials.

Dr. Friedlich helped pioneer translational suppression as a strategy for treating neurodegenerative disease. In 2007, he co-discovered a post-transcriptional regulatory element in the Parkinson's disease alpha-synuclein transcript, leading to the discovery that alpha-synuclein and the Alzheimer amyloid precursor protein are controlled through a common intracellular pathway. A number of translational suppressors are now in pre-clinical development.

Dr Friedlich is also a board-certified Psychiatirst interested in mechanism-based development of neutraceuticals for the treatment of neuropsychiatric disorders. He is co-investigator on a number of clinical trials in the Bipolar Clinic & Research Program at Mass General Hospital, and he maintains a clinical practice.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad